Jian-Ming Xu
徐建明
MD, PhD
Professor; Director, Department of Gastrointestinal Oncology教授；消化肿瘤科主任
👥Biography 个人简介
Jian-Ming Xu, MD, PhD is Professor and Director of the Department of Gastrointestinal Oncology at PLA General Hospital (301 Hospital) in Beijing, and is one of China's most prominent clinical investigators in biliary tract and pancreatic cancers. He has led major Chinese national and international collaborative trials including studies of IDH1 inhibitors (ivosidenib) in IDH1-mutant cholangiocarcinoma and combination immunotherapy regimens in biliary and pancreatic malignancies. His large patient series from China's most active oncology center have provided critical data on molecular profiles and treatment outcomes in Asian populations with these rare cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IDH1 Inhibitor Trials in Cholangiocarcinoma
Served as principal Chinese investigator on the ClarIDHy phase III trial evaluating ivosidenib in IDH1-mutant advanced cholangiocarcinoma, and led subsequent combination studies pairing IDH inhibition with PD-1 blockade in Chinese and international patient cohorts.
Molecular Profiling of Chinese Biliary Tract Cancer Patients
Led prospective genomic profiling of the largest Chinese cohort of biliary tract cancers, revealing population-specific mutation frequencies for FGFR2, IDH1/2, ERBB2, and KRAS that inform optimal targeted therapy strategies in Asian patients.
Immunotherapy Combinations in GI Cancers
Designed and led Chinese trials evaluating PD-1/PD-L1 inhibitors combined with chemotherapy in advanced PDAC and biliary cancers, contributing to the evidence base for sintilimab and camrelizumab approvals and NMPA guideline updates in China.
Representative Works 代表性著作
Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Chinese Subgroup Analysis
ESMO Open (2022)
Demonstrated consistent efficacy and safety of ivosidenib in Chinese patients with IDH1-mutant CCA, supporting regulatory review by China's NMPA.
Genomic Landscape of Biliary Tract Cancers in a Chinese Population: A Prospective Cohort Study
Journal of Hepatology (2023)
Comprehensive molecular profiling of 620 Chinese BTC patients defining mutation spectrum, co-alterations, and actionable target frequencies with therapeutic implications.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 徐建明 的研究动态
Follow Jian-Ming Xu's research updates
留下邮箱，当我们发布与 Jian-Ming Xu（PLA General Hospital (301 Hospital), Beijing）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment